Rein Therapeutics Inc.

RNTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.79

-$0.01 (-1.25%)

At close: Sep 21, 2026, 4:00 PM ET

$0.80

+$0.01 (+1.27%)

Pre-market: Sep 22, 2026, 4:06 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $22.21M

Enterprise Value $-18.44M

Beta 1.37

Average Volume 723.79K

Shares Outstanding (Diluted) 67.08M

Shares Change YoY 177.35%

Institutional Ownership 37.54%

Exchange NASDAQ

ISIN US00887A2042

Price Performance

Price Change 1M -3.7%

Price Change 3M -18.4%

Price Change 6M -39.2%

Price Change YTD -36.8%

Price Change 1Y -33.0%

Price Change 3Y -54.9%

Price Change 5Y -54.9%

1M CAGR (ann.) -2.8%

1Y CAGR (ann.) -30.9%

5Y CAGR (ann.) N/A

All-Time CAGR -42.7%

Valuation

PE Ratio -0.46

Forward PE N/A

PEG Ratio -0.01

Forward PEG -0.40

PS Ratio N/A

Forward PS 0.20

PB Ratio 0.40

P/FCF Ratio -1.18

P/Adj. FCF Ratio -1.06

P/OCF Ratio -1.27

EV/Sales N/A

EV/EBIT 0.85

EV/EBITDA 0.88

EV/FCF 0.98

Earnings Yield -217.7%

FCF Yield -84.8%

Adj. FCF Yield -93.9%

Financial Health

Net Cash $40.65M

Total Debt $0

Cash & Short-Term Investments $40.65M

Total Assets $65.97M

Current Ratio 4.27

Quick Ratio 4.27

Debt / Equity Ratio 0.00

Debt / EBITDA -0.00

Debt / FCF -0.00

OCF / Debt N/A

Interest Coverage 0.00

Altman Z-Score -8.04

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -10.8%

Returns

Return on Assets -75.4%

Return on Equity -234.4%

Return on Invested Capital -36.4%

Return on Capital Employed -36.9%

Return on Tangible Assets -107.8%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 30.0%

EPS CAGR 5Y 24.9%

EPS CAGR 10Y N/A

FCF CAGR 3Y -9.6%

FCF CAGR 5Y 7.0%

FCF CAGR 10Y 3.0%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 2

EPS Growth Next 3Y 22.1%

Revenue Growth Next 3Y N/A

Earnings Date Nov 12, 2026

EPS Estimate (next Q) -$0.10

EPS Growth Est (next Q) -52.4%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $6

Price Target Upside 659.5%

Cash Flow

Operating Cash Flow $-18.83M

Free Cash Flow $-18.83M

Adj. Free Cash Flow $-20.86M

FCF Per Share -$0.62

OCF Per Share -$0.62

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $0

Operating Income $-20.76M

EBITDA $-21.04M

Net Income $-49.76M

EPS (Diluted) -$1.72

Revenue / Employee N/A

Profit / Employee $-4.98M

Employees 10